Show simple item record

dc.contributor.authorMiah, ABen_US
dc.contributor.authorBhide, SAen_US
dc.contributor.authorDel Rosario, Len_US
dc.contributor.authorMatthews, Jen_US
dc.contributor.authorNicol, Ren_US
dc.contributor.authorTanay, MAen_US
dc.contributor.authorGupta, Sen_US
dc.contributor.authorZaidi, SHen_US
dc.contributor.authorNewbold, KLen_US
dc.contributor.authorHarrington, KJen_US
dc.contributor.authorNutting, CMen_US
dc.date.accessioned2017-05-02T10:08:03Z
dc.date.issued2016-08en_US
dc.identifier.citationClinical oncology (Royal College of Radiologists (Great Britain)), 2016, 28 (8), pp. e61 - e67en_US
dc.identifier.issn0936-6555en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/626
dc.identifier.eissn1433-2981en_US
dc.identifier.doi10.1016/j.clon.2016.01.012en_US
dc.description.abstract<h4>Aims</h4>To determine the toxicity and tumour control rates after chemo-intensity-modulated radiotherapy (chemo-IMRT) for locally advanced nasopharyngeal cancers (LA-NPC).<h4>Materials and methods</h4>Patients with LA-NPC were enrolled in a trial to receive induction chemotherapy followed by parotid-sparing chemo-IMRT. The primary site and involved nodal levels received 65 Gy in 30 fractions and at risk nodal levels received 54 Gy in 30 fractions. Incidence of ≥grade 2 subjective xerostomia was the primary end point. Secondary end points included incidences of acute and late toxicities and survival outcomes.<h4>Results</h4>Forty-two patients with American Joint Committee on Cancer stages II (12%), III (26%) and IV (62%) (World Health Organization subtype: I [5%]; II [40%]; III [55%]) completed treatment between January 2006 and April 2010 with a median follow-up of 32 months. Incidences of ≥grade 2 acute toxicities were: dysphagia 83%; xerostomia 76%; mucositis 97%; pain 76%; fatigue 99% and ototoxicity 12%. At 12 months, ≥grade 2 subjective xerostomia was observed in 31%, ototoxicitiy in 13% and dysphagia in 4%. Two year locoregional control was 86.2% (95% confidence interval: 70.0-94.0) with 2 year progression-free survival at 78.4% (61.4-88.6) and 2 year overall survival at 85.9% (69.3-93.9).<h4>Conclusions</h4>Chemo-IMRT for LA-NPC is feasible with good survival outcomes. At 1 year, 31% experience ≥grade 2 subjective xerostomia.en_US
dc.formatPrint-Electronicen_US
dc.format.extente61 - e67en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectHumansen_US
dc.subjectNasopharyngeal Neoplasmsen_US
dc.subjectDisease-Free Survivalen_US
dc.subjectFollow-Up Studiesen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectMiddle Ageden_US
dc.subjectFemaleen_US
dc.subjectMaleen_US
dc.subjectRadiotherapy, Intensity-Modulateden_US
dc.subjectChemoradiotherapyen_US
dc.subjectInduction Chemotherapyen_US
dc.titleInduction Chemotherapy Followed by Chemo-intensity-modulated Radiotherapy for Locally Advanced Nasopharyngeal Cancer.en_US
dc.typeJournal Article
dcterms.dateAccepted2015-12-30en_US
rioxxterms.versionofrecord10.1016/j.clon.2016.01.012en_US
rioxxterms.licenseref.startdate2016-08en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfClinical oncology (Royal College of Radiologists (Great Britain))en_US
pubs.issue8en_US
pubs.notes12 monthsen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume28en_US
pubs.embargo.terms12 monthsen_US
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorHarrington, Kevinen_US
dc.contributor.icrauthorZaidi, Shane Haideren_US
dc.contributor.icrauthorNutting, Chrisen_US
dc.contributor.icrauthorMiah, Aishaen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record